{
    "clinical_study": {
        "@rank": "25227", 
        "acronym": "FASTFOOD", 
        "arm_group": [
            {
                "arm_group_label": "Fasting-Fed", 
                "arm_group_type": "Active Comparator", 
                "description": "blood sampling on 3 consecutive days; by randomization, drug treatment as follows: day 1, HRZE as iv therapy; on day 2, HRZE as oral therapy in fasting condition (2 hours before meals); and on day 3 HRZE as oral therapy in fed condition (after meals)."
            }, 
            {
                "arm_group_label": "Fed-Fasting", 
                "arm_group_type": "Active Comparator", 
                "description": "blood sampling on 3 consecutive days; by randomization, drug treatment as follows: day 1, HRZE therapy as iv therapy; day 2, HRZE as oral therapy in fed condition, and on day 3, HRZE as oral therapy in fasting condition"
            }
        ], 
        "brief_summary": {
            "textblock": "WHO recommends to take TB drugs while fasting: if TB drugs are taken with food, perhaps drug\n      concentrations are too low; on the other hand: if this is not tolerated, drugs could also be\n      taken with food.\n\n      Do lower drug concentrations - with improved adherence to therapy - outweigh the\n      disadvantage of lower drug blood concentrations over time? How exactly do the drug\n      concentrations over time (pharmacokinetics) compare between fasting and fed conditions,\n      especially in the early stage of TB treatment when patients are relatively sick, and\n      relatively poorly tolerate TB drugs?"
        }, 
        "brief_title": "HRZE FASTED/FED IN NEWLY DIAGNOSED TB", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Tuberculosis", 
        "condition_browse": {
            "mesh_term": "Tuberculosis"
        }, 
        "detailed_description": {
            "textblock": "To evaluate the influence of concomitant food ingestion on the pharmacokinetics of HRZE in\n      newly diagnosed TB patients To evaluate the influence of early disease on the PK parameters\n      of HRZE in TB patients To compare the pharmacokinetics of HRZE in the early stage of disease\n      with the pharmacokinetics of HRZE in more stable condition in newly diagnosed TB patients To\n      evaluate adverse events of HRZE in TB patients"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with TB who are starting with HRZE therapy\n\n          -  Age > 18 years old\n\n          -  Written informed consent\n\n        Exclusion Criteria:\n\n          -  Use of antacids, which cannot be discontinued for study days\n\n          -  Active, unstable hepatic disease (with jaundice, HRZ)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 25, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02121314", 
            "org_study_id": "UGM-RuG-UMCG-TB-001"
        }, 
        "intervention": {
            "arm_group_label": [
                "Fasting-Fed", 
                "Fed-Fasting"
            ], 
            "intervention_name": "intravenous administration of 1st line TB drugs, to compare with oral regimens (isoniazid, rifampin, and ethambutol)", 
            "intervention_type": "Drug", 
            "other_name": "intravenous versus oral isoniazid, rifampin, and ethambutol"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Ethambutol", 
                "Isoniazid", 
                "Rifampin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "TB", 
            "bioavailability", 
            "HRZE", 
            "fasting", 
            "fed"
        ], 
        "lastchanged_date": "April 22, 2014", 
        "location": {
            "contact": {
                "email": "a.m.i.saktiawati@umcg.nl", 
                "last_name": "Antonia Morita Saktiawati, MD"
            }, 
            "contact_backup": {
                "email": "ysubronto@yahoo.com", 
                "last_name": "Yanri Subronto, MD PhD"
            }, 
            "facility": {
                "address": {
                    "city": "Yogyakarta", 
                    "country": "Indonesia"
                }, 
                "name": "Sardjito Central Hospital"
            }, 
            "investigator": {
                "last_name": "Ning Rintiswati, MD", 
                "role": "Sub-Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Indonesia"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Influence of Fasting and Food on the Pharmacokinetics of Isoniazid, Rifampicin, Pyrazinamide, and Ethambutol in Newly Diagnosed TB Patients", 
        "other_outcome": {
            "description": "Parameters which may influence the pharmacokinetics of HRZE will be measured at start and end of the study.\nBMI, i.e. body weight and length\nage\ngender\nethnicity\nco-morbidity, for instance HIV/AIDS, diabetes (only at start)\nco-medication: especially HIV medication, prednisolone (may lower INH concentration), antacids (may lower absorption of HRE concentration)\nchemistry: liver function, renal function, hemoglobulin, albumin, bilirubin\npharmacogenetics", 
            "measure": "confounding factors for primary and secondary outcomes", 
            "safety_issue": "Yes", 
            "time_frame": "weeks 1 and 8"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Yogyakarta, Indonesia: Ethics Committee Universitas Gadjah Mada, Sardjito Teaching Hospital", 
                "Indonesia: National Agency of Drug and Food Control"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "pharmacokinetics (AUC0-8, Cmax, and Tmax); comparison between TB patients who take HRZE concomitant with food and TB patients who take HRZE concomitant without food, weeks 1 and 8 of treatment", 
                "measure": "pharmacokinetics", 
                "safety_issue": "No", 
                "time_frame": "3 days - week 1 and week 8"
            }, 
            {
                "description": "PK curves from venous blood specimens sampled from indwelling venous catheter", 
                "measure": "pharmacokinetics (AUC0-8, Cmax, and Tmax) of HRZE", 
                "safety_issue": "No", 
                "time_frame": "11 time points, 3 consecutive days - wk 1 & 8"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02121314"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University Medical Centre Groningen", 
            "investigator_full_name": "Tjip van der Werf", 
            "investigator_title": "Professor, Infectious Diseases & Tuberculosis", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "tolerance - acceptance; vomiting, refusal", 
            "measure": "To evaluate adverse events of HRZE, week 1 and 8 - while taking food or not", 
            "safety_issue": "Yes", 
            "time_frame": "week 1 -  week 8"
        }, 
        "source": "University Medical Centre Groningen", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "University of Groningen", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Universitas Gadjah Mada", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "University Medical Centre Groningen", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}